Patents Assigned to ACADEMY OF MILITARY MEDICAL SCIENCES
-
Patent number: 7973010Abstract: The present invention relates to a nucleic acid molecule as set forth in SEQ ID NO:1 comprising a polynucleotide sequence encoding full length chicken type II collagen (CCII), or a fragment thereof in possession of the same biological functions as well as CCII encoded thereof. It also relates to a method for producing CCII, and its use in the manufacture of a medicament for treating and/or preventing rheumatoid arthritis (RA). The invention specifically relates to a pharmaceutical composition for treating and/or preventing osteoarthritis and RA, to a food or beverage composition, and to a food additive composition, containing CCII prepared according to the method described in this invention, and the use of the nucleic acid molecules of the present application in gene therapy.Type: GrantFiled: November 14, 2003Date of Patent: July 5, 2011Assignee: Affiliated Hospital of Academy of Military Medical Sciences, PLAInventors: Yongzhi Xi, Caixia Xi
-
Publication number: 20110091420Abstract: Disclosed are an injectable sustained-release pharmaceutical formulation and a process for preparing the same. In some embodiments, the formulation comprises an active ingredient in a therapeutically effective amount, an amphipathic molecule, an organic acid and/or a salt thereof which is hardly soluble in water, and an oily solvent. The injectable sustained-release pharmaceutical formulation provides a good sustained-release effect for various active ingredients, in particular peptides, proteins, nucleic acids and saccharides.Type: ApplicationFiled: March 20, 2009Publication date: April 21, 2011Applicants: Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, People Liberation Ar, Chengdu Yiping Pharmaceutical Science Development Co., Ltd.Inventors: Keliang Liu, Dongqin Quan, Yuanjun Liang, Qingbin Meng, Chenhong Wang, Junlin He, Qiyan Jia, Sicheng Li
-
Publication number: 20110009427Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound of formula (I), and the use of the compound for the preparation of a medicament for treating and/or preventing human peroxisome proliferators activated receptor ? (hPPAR?)-associated diseases and risk factors.Type: ApplicationFiled: July 18, 2008Publication date: January 13, 2011Applicant: INSTITUE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINAInventors: Song Li, Yanbo Yang, Junhai Xiao, Wu Zhong, Zhibing Zheng, Xingzhou Li, Yunde Xie, Lili Wang, Hongying Liu
-
Publication number: 20100234291Abstract: Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof.Type: ApplicationFiled: December 22, 2009Publication date: September 16, 2010Applicants: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA, Beijing Sanly Sci-Tech Develop Inc. Ltd.Inventors: Zuze Wu, Aiping Yu, Chuanling Zhang, Zhongxiong Tang
-
Publication number: 20100227815Abstract: The present invention relates to site-specific PEGylated linear salmon calcitonin analogues, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.Type: ApplicationFiled: June 4, 2008Publication date: September 9, 2010Applicant: Institute of Pharmacology and Toxicology Academy Of Military Medical ScienceInventors: Keliang Liu, Jiankun Qie, Zhixia Yang, Yuanjun Liang, Ying Wang, Zehui Gong, Huajin Dong
-
Patent number: 7727965Abstract: The present invention relates to C-Glycosylisoflavones having alkylaminoalkoxyl substituent and pharmaceutically acceptable salts thereof, a process for the preparation thereof, pharmaceutical compositions comprising an effective amount of a compound of the formula (I), and to the use of these compounds or compositions for the treatment or prevention of cardio- and cerebrovascular diseases, in particular for the treatment of various cardiocerebral hypoxic-ischemic diseases, for the treatment or prevention of diabetes mellitus and complications thereof, and for the treatment or prevention of chemical poisoning, in particular alcoholism.Type: GrantFiled: July 2, 2004Date of Patent: June 1, 2010Assignees: Hainan Yangpu New & Special Medicine Co., Ltd., Institute of Radiation Medicine, Academy of Military Medical Sciences, PLAInventors: Lin Wang, Qiujun Lu, Shengqi Wang, Tao Peng, Xiaowei Zhu, Shouguo Zhang, Jianping Ren, Lu Li, Ling Han, Yiguang Jin, Fengsheng Che
-
Publication number: 20100120173Abstract: Provided is a strip-assembled immunochromatographic disc, containing: a base, a lid engaged with the base and a draining piece disposed between the strips on the base and the lid, wherein a sampling opening is disposed on the lid directly facing to the draining piece, and the said sampling opening intercommunicates to a draining groove provided on the inner side of the lid which is formed by a plurality of draining channels; several strip stages are provided on the base with their location and number corresponding to those of the draining channels provided on the lid, and the edge of the draining piece laps to the sample pads of the strips carried on the stage adjacent to one end of the sampling opening. Also provided is a method of performing multiplexed immnochromatographic detection using the strip disc to accomplish the detection of multiple target analytes in one sample in an assay.Type: ApplicationFiled: April 23, 2007Publication date: May 13, 2010Applicant: Institute of Microbiology and Epidemiology, Academy of Military Medical ScienceInventors: Lei Zhou, Zongmin Du, Ruifu Yang, Huijie Huang
-
Publication number: 20090221487Abstract: Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.Type: ApplicationFiled: November 11, 2006Publication date: September 3, 2009Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Keliang Liu, Jiankun Qie, Jinbo Ma, Jianquan Zheng, Sijian Dong, Sijian Dong, Wenxia Zhou, Chunhui Qi
-
Patent number: 7560473Abstract: The present invention provides amine derivatives represented by formula I, its isomers, racemes or optical isomers, pharmaceutical salts thereof, its amides or esters, pharmaceutical compositions containing said compounds and the preparation methods thereof. The invention also relates to the use of the above mentioned compounds in the preparation of drugs for the prophylaxis or treatment of cardiovascular diseases, diabetes, bronchial and urinary smooth muscle spasm as well as ischemic and anoxic nerve injury. The above compounds can be used to treat hypertension, angina diaphragmatic, myocardial infarction, congestive heart failure, arrhythmia, diabetes, spasmodic bronchial diseases, spasmodic bladder or ureter diseases, and depression.Type: GrantFiled: January 21, 2002Date of Patent: July 14, 2009Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences, P.L.A.Inventors: Hai Wang, Liuhong Yun, Huasong Feng, Fulin Li, Xingchun Tang, Huamei He, Rifang Yang, Wenyu Cui, Qixiu Gao, Gang Hu, Rusheng Zhao, Wei Liu, Chaoliang Long, Lin Wang, Xinqiang Lu, Lijun Liu, Yuan Yan
-
Publication number: 20090075912Abstract: The invention disclosed the use of timosaponin BII in the preparation of a medicament or product for the prevention and treatment of stroke. The experiments prove that timosaponin BII can improve the neurological symptoms of cerebral ischemic rat, reduce infarct size, relieve brain water edema, improve hemorheology, reduce inflammatory injury of cerebral ischemia.Type: ApplicationFiled: April 21, 2005Publication date: March 19, 2009Applicant: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLAInventors: Baiping Ma, Quiping Xu, Yang Zhao, Chengqi Xiong, Dawei Tan
-
Publication number: 20090012277Abstract: A method for preparation of Timosaponin BII, which uses Chinese traditional medicine Rhizoma Anemarrhenae or fresh rhizoma or fibrous root of Anemarrhena asphodeloides Bge. as raw material, and comprises isolation of Timosaponin BII by one or more processes selected from solvent extraction, resin adsorption, polyamide chromatography, reversed phase column chromatography, Sephadex LH-20 column chromatography, etc, combining with conventional drying method such as reduced pressure drying, freeze drying, spray drying, and so on. Timosaponin BII obtained by the present method is of over 90% purity, and the method is simple, practicable and suitable for industrial production.Type: ApplicationFiled: April 21, 2005Publication date: January 8, 2009Applicant: Institute Of Radiation Medicine, Academy of Military Medical Sciences, PLAInventors: Baiping Ma, Hao Chen, Chengqi Xiong, Liping Kang, Jie Zhang
-
Patent number: 7384920Abstract: This invention relates to a new use of stilbene derivatives or pharmaceutically acceptable salts thereof, especially in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus associated diseases.Type: GrantFiled: July 26, 2001Date of Patent: June 10, 2008Assignees: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLA, Beijing Luyin Lihua Pharmaceutical Science and Technology Development Company LtdInventors: Junlin Li, Zuze Wu, Lizhen Yuan, Qiang Li, Zhongxiong Tang
-
Patent number: 7262183Abstract: This invention relates to substituted 5-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R1, R2, R3, R4, V, W, X, Y, and Z are as defined in the description; their preparation methods, compositions comprising the same, and their use as inhibitors of FK560 binding proteases (FKBPs) activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injuries or other related diseases.Type: GrantFiled: December 5, 2002Date of Patent: August 28, 2007Assignees: Instititute of Pharmacology and Toxicology, Academy of Military Medical Sciences P.L.A.Inventors: Song Li, Liqin Zhao, Lili Wang, Beifen Shen, Liuhong Yun
-
Patent number: 7119100Abstract: The present invention relates to oripavine derivatives of formula (I), wherein R1 is hydrogen or methyl, R2 is methyl, cyclopropyl methyl, cyclobutyl methyl or allyl, R3 is thiophenyl ethyl or cycloalkyl methyl where the cycloalkyl has 3 to 6 carbon atoms, or non-toxic pharmaceutically acceptable salts thereof. These compounds can be used for the preparation of analgesics or abstinence agents of opium habit-forming drugs.Type: GrantFiled: September 13, 2002Date of Patent: October 10, 2006Assignees: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences, P.L.A. China, Zhejiang Xianju Pharmaceuticals Co. Ltd.Inventors: Bohua Zhong, Zehui Gong, Yaping Wang, Yongshao Liu
-
Patent number: 7049301Abstract: This invention relates to quercetin derivative, its preparation, and a pharmaceutical combination, as well as their medical uses for the prevention or treatment of diseases related to 5HT1A receptor or neuron cell damages, including Alzeheimer's disease, drug or alcohol dependence, sleep disorders or panic state; and for delaying senility, improving learning and memory, preventing and treatment of neuron cell damages caused by various kinds of cerebral damages.Type: GrantFiled: September 26, 2003Date of Patent: May 23, 2006Assignee: Academy of Military Medical Sciences Institute of Pharmacology and ToxicologyInventors: Yimin Zhao, Ming Yang, Yunfeng Li, Xinhui Luan, Zhipu Luo
-
Patent number: 6953780Abstract: The instant invention relates to some tripeptide derivatives having activity against endothelin a process for preparing them, pharmaceutical composition containing the same and their use in prevention or treatment of some diseases associated with endothelin.Type: GrantFiled: June 21, 2001Date of Patent: October 11, 2005Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences, P.L.A.Inventors: Keliang Liu, Wensheng Yu, Yuanjun Liang, Hai Wang, Yufen Zhao, Zhenkai Ding
-
Publication number: 20040132671Abstract: This invention relates to quercetin derivative, its preparation, and a pharmaceutical combination, as well as their medical uses for the prevention or treatment of diseases related to 5HT1A receptor or neuron cell damages, including Alzeheimer's disease, drug or alcohol dependence, sleep disorders or panic state; and for delaying senility, improving learning and memory, preventing and treatment of neuron cell damages caused by various kinds of cerebral damages.Type: ApplicationFiled: September 26, 2003Publication date: July 8, 2004Applicant: ACADEMY OF MILITARY MEDICAL SCIENCES INSTITUTE OF PHARMACOLOGY AND TOXICOLOGYInventors: Yimin Zhao, Ming Yang, Yunfeng Li, Xinhui Luan, Zhipu Luo
-
Patent number: 6331565Abstract: This invention relates to the new use of dicaffeoylquinic acid derivatives for treating Hepatitis B and diseases associated with retrovirus (such as HIV), the new caffeoylquinic acid derivatives and the composition containing the same.Type: GrantFiled: March 1, 1999Date of Patent: December 18, 2001Assignee: Institute of Radiation Medicine Academy of Military Medical Sciences of the PLAInventors: Junxing Dong, Zhongming Tang, Zhibao Mi, Bingji Wang
-
Patent number: 5677331Abstract: The invention relates to a synergistic antimalarial composition which comprises the antimalarial agent benflumetol and also an antimalarial agent from the artemisinine group such as artemether. The composition can be formulated into solid dosage forms such as tablets and is useful for the treatment of drug resistant malaria.Type: GrantFiled: March 23, 1994Date of Patent: October 14, 1997Assignees: Ciba-Geigy AG, Institute of Microbiology and Epidemiology, Academy of Military Medical SciencesInventors: Yiqing Zhou, Dianxi Ning, Shufen Wang, Deben Ding, Guofu Li, Chengqi Shan, Guangyu Liu